Last updated 22 days ago
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
1099 patients around the world
Available in Mexico
AstraZeneca
1099Patients around the world
This study is for people with
Chronic obstructive pulmonary disease
Copd
Requirements for the patient
To 130 Years
All Gender
Medical requirements
- Participant must be ≥ 40 years of age and capable of giving signed informed consent.Documented diagnosis of COPD for at least one year prior to enrolment.Post BD FEV1/FVC < 0.70 and post-BD FEV1 >20% of predicted normal value.Documented history of ≥ 2 moderate or ≥ 1 severe COPD exacerbations within 12 months prior to enrolment.Documented optimized inhaled dual or triple therapy at a stable dose for at least 3 months prior to enrolment.Smoking history of ≥ 10 pack-years.CAT total score ≥10, with each of the phlegm (sputum) and cough items with a score ≥ 2.
- Clinically important pulmonary disease other than COPD.Radiological findings suggestive of a respiratory disease other than COPD that is significantly contributing to the participant's respiratory symptoms.Current diagnosis of asthma, prior history of asthma, or asthma-COPD overlap. Childhood history of asthma is allowed and defined as asthma diagnosed and resolved before the age of 18.Any unstable disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric disorder, major physical and/or cognitive impairment that could affect safety, study findings or participants ability to complete the study.COPD exacerbation, within 2 weeks prior to randomization, that was treated with systemic corticosteroids and/or antibiotics, and/or led to hospitalization.Active significant infection within the 4 weeks prior to randomization, pneumonia within 6 weeks prior to randomization, or medical condition that predisposes the participant to infection.Suspicion of, or confirmed, ongoing SARS-CoV-2 infection.Significant COVID-19 illness within the 6 months prior to enrolment.Unstable cardiovascular disorder.Diagnosis of cor pulmonale, pulmonary arterial hypertension and/or right ventricular failure.History of known immunodeficiency disorder, including a positive test for HIV-1 or HIV 2.History of positive test or treatment for hepatitis B or hepatitis C (except for cured hepatitis C)Evidence of active liver disease, including jaundice during screening.Malignancy, current or within the past 5 years, except for adequately treated non-invasive basal cell and squamous cell carcinoma of the skin and cervical carcinoma-in-situ treated with apparent success more than one year prior to enrolment. Suspected malignancy or undefined neoplasms.Participants who have evidence of active TB.Participants that have previously received tozorakimab.Any clinically significant abnormal findings in physical examination, vital signs, ECG, or laboratory testing during the screening period, which in the opinion of the investigator may put the participant at risk because of their participation in the study, or may influence the results of the study, or the participant's ability to complete the entire duration of the study.Active vaping of any products or using smoked marijuana within the 6 months prior to randomization and during the study.
StudyOBERON
SponsorAstraZeneca
Study typeInterventional
Conditions
Copd
Requirements
To 130 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT05166889
